02607.HK
Shanghai Pharmaceuticals Holding Co., Ltd.
HKSE · Healthcare · Medical - Distribution · CN
HKD 11.01
−0.36%Year over year
Reported trailing growth
- Revenue
- +4.0%
- EBITDA
- +29.2%
- EBIT
- -20.6%
- EPS
- -22.1%
- Free cash flow
- +302.0%
- Operating cash flow
- +901.3%
Forward estimates
Based on analyst estimates
- Revenue
- +0.2%
- EBITDA
- -11.4%
- EPS
- +5.5%
Three-year CAGR
- Revenue
- +6.9%
- EBITDA
- +4.9%
- EBIT
- +3.3%
- Net income
- +0.6%
- EPS
- -1.5%
- Free cash flow
- +23.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026